HDAC9 and plasma cell myeloma: In addition, P5091 inhibits tumor growth and synergizes with other chemotherapeutic agents such as lenalidomide, HDAC inhibitor or dexamethasone to induce synergistic anti-multiple myeloma effect [32, 33].Our data shows P22077 significantly enhances the sensitivity and overcomes resistance of Dox in HCC.